<DOC>
	<DOCNO>NCT02985242</DOCNO>
	<brief_summary>This prospective , randomize , active control , two-arm parallel , double-blind , monocenter phase IV clinical trial . The trial compare empagliflozin glimepiride patient type 2 diabetes mellitus addition standard care treatment . Patients type 2 diabetes mellitus 18 80 year age recruit clinical trial randomly allocate either receive empagliflozin glimepiride . The assumption study empagliflozin slow diabetic retinopathy progression rate thus low microaneurysm formation rate compare subject treat glimepiride substantially decrease cellular glucotoxicity achieve .</brief_summary>
	<brief_title>Empagliflozin Reduces Progression Diabetic Retinopathy Patients With High Risk Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>1. woman men 18 80 year age 2. type 2 diabetes mellitus ≥ 1 year 3. early moderate stage diabetic retinopathy ( ETDRS : 20 ( microaneurysms ) 35 ( microaneurysms/ hemorrhage and/or hard exsudates ) ) one eye 4. stable HbA1c ( ± 0.3 % ) least 12 week 5. antidiabetic treatment either diet , metformin , DPP4 , GLP1 , pioglitazone , acarbose , respective combination 6 . HbA1c ≥ 7.0 ≤ 10.0 % 7. body mass index &lt; 46 kg/m2 8. office blood pressure ≤ 150/95 mmHg ( confirmed second day ; 24h ambulatory blood pressure measurement ( ABPM ) allow check accuracy office value ; inclusion 24h mean blood pressure ≤ 145/90 mm Hg possible ) ; patient hypertension treat accord current treatment guideline 9. either woman without childbearing potential define : least 6 week surgical sterilization bilateral tubal ligation bilateral oophorectomy hysterectomy ≥ 50 year postmenopausal state &gt; 1 year &lt; 50 year postmenopausal state &gt; 1 year serum follicle stimulate hormone ( FSH ) &gt; 40 IU/l serum estrogen &lt; 30 ng/l negative estrogen test , screen woman childbearing potential negative serum beta human chorionic gonadotropin ( ßhCG ) pregnancy test screen agree meet one follow criterion time screening , study period 4 day follow last administration study medication : correct use one follow accept contraception method : hormonal contraceptive ( combined oral contraceptive , implant , transdermal patch , hormonal vaginal device injection prolong release ) , intrauterine device ( IUD/IUS ) double barrier method , e.g . condom occlusive cap ( diaphragm cervical/vault cap ) spermicide ( foam , gel , film , cream suppository ) true abstinence ( periodic abstinence withdrawal acceptable method contraception ) sexual relationship female partner sterile male partner 10. sign write informed consent willingness comply treatment followup procedures 11. capability understanding investigational nature , potential risk benefit clinical trial 1 . Type 1 diabetes 2. uncontrolled diabetes mellitus type 2 fast glucose &gt; 13.3 mmol/l confirm second day 3. know suspected hypersensitivity empagliflozin , glimepiride , excipients ; / know suspected hypersensitivity sulfonylurea , sulfonamide SGLT2 inhibitor general 4. history multiple severe hypoglycemic episode within last two year 5. use Insulin , SGLT2inhibitor , sulfonylurea derivate glinide within past 3 month 6. clinical significant macular edema eye indication intravitreal antiVEGF treatment eye screen baseline visit 7. eye disease pathology prevent clear ophthalmoscopy evaluation study parameter , thus allow study participation accord investigator´s judgment , ( ) vitreous hemorrhage , mature cataract , macular pathology diabetic maculopathy 8. history ketoacidosis metabolic acidosis 9. use loop diuretic 10. history &gt; 1 urogenital infection/year 11. history stroke , transient ischemic attack ( TIA ) , instable angina pectoris myocardial infarction within last 3 month prior baseline visit 12. congestive heart failure New York Heart Association ( NYHA ) III IV , NYHA IV patient treat pioglitazone 13. severe valvular leave ventricular outflow obstruction disease need intervention ; 14. atrial fibrillation/flutter mean ventricular response rate rest &gt; 100 beat per minute 15. chronic low urinary tract infection ( simple asymptomatic bacteriuria ) 16. eGFR &lt; 60 ml/min/1,73 m2 ( MDRDformula , confirm second day ) 17. chronic diarrhea , clinical sign volume depletion hematocrit &gt; 48 % ( woman ) &gt; 53 % ( men ) 18. elevate risk volume depletion , e.g . history severe volume depletion require medical therapy 19. chronic liver disease ( include know active hepatitis ) and/or screen alanine transaminase ( ALT ) aspartate transaminase ( AST ) &gt; 3 x upper limit normal ( ULN ) ( confirmed second day ) 20 . Subjects know seropositivity human immunodeficiency virus . 21. acute illness screen randomization accord judgement investigator patient 22. drug alcohol abuse 23. psychosomatic psychiatric disease require hospitalization last 12 month 24. clinical evidence current malignancy exception basal cell squamous cell carcinoma skin , cervical intraepithelial neoplasia ( 5 year prior randomization ) 25. medical surgical intervention plan next 13 month randomization allow study participation accord investigator´s judgment 26. current participation clinical trial participation another clinical trial within 30 day screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>